Internal medicine

Immunotherapy

Esophagus

Disease

Trastuzumab

Pembrolizumab

Gastroesophageal Junction

Open label

Gastroenterology

Cancer

Oncology

Gastro-

Reflux

Breast cancer

Adenocarcinoma

Clinical trial

Medicine

The Lancet Oncology

Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity in HER2-positive metastatic oesophagogastric cancer. A randomised phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric cancer is underway.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial